AMC Health Partners with Icahn School of Medicine on Televideo-Enabled Prostate Cancer Clinical Trial
Technology Provides Access to Patients Living Far from Study Site
Today, AMC Health announced the first patient enrolled in a prostate cancer clinical trial deploying televideo, at Mount Sinai's Icahn School of Medicine in Manhattan. The trial is testing whether the antidiabetic medication metformin may slow the progression of recurrent prostate cancer. AMC Health, a leading provider of proven mobile health solutions, has pioneered the use of televideo in clinical trials and is providing this capability for the study.
Matthew Galsky, M.D., Associate Professor of Medicine at Icahn School of Medicine, Director of Genitourinary Medical Oncology at Tisch Cancer Center at Mount Sinai and the principal investigator, said, "Our prior research demonstrates that geographic barriers and travel burdens prevent many patients from participating in clinical trials. This televideo technology by AMC Health provides a solution, connecting patients remotely with our study site. Patients living at great distances from Mount Sinai may come for an initial visit, but may be unable to travel monthly for follow-up visits, preventing them from participating in clinical trials. 'Video visits' make their participation possible."
The protocol for the trial was developed with input from patients, physicians and researchers, using an innovative crowd-sourcing platform developed by Transparency Life Sciences, a New York-based open-source pharmaceutical development company. "I developed a draft protocol," Dr. Galsky explained, "and 'the crowd' used Transparency's Internet platform to make significant improvements to the trial design."
"This study introduces innovative technologies that can improve future clinical trials," according to John Holland, Senior VP for Research in the Clinical Trials Division of AMC Health, "and we are honored to partner with Dr. Galsky and Mount Sinai in this effort."
Tweet This: Innovative #ClinicalTrial creates possible new treatment for prostate #cancer |http://bit.ly/1tE5k7o @AMCHealth @MountSinaiNYC #telehealth
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
